COVID-19 in Russia: Evolution of Views on the Pandemic. Report II

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Over the two years of the novel coronavirus infection (COVID-19) pandemic, there has been an evolution of views in various fields of medicine, which has led to a powerful development of scientific research in the field of epidemiology, clinic, diagnosis and therapy of COVID-19. This article discusses the evolution of views and approaches to the study of the clinic and therapy of COVID-19. The symptoms and aggravation of the course of cardiovascular diseases with COVID-19 have been established. The main strategy for organizing surgical care for patients with COVID-19 is indicated. The main criteria for the treatment of COVID-19, the need to prescribe SGCS on an individual basis, and the need to search for new methods of anti-inflammatory therapy for COVID-19, one of which may be the use of alkylating drugs in ultra-low doses, are described.

Full Text

Restricted Access

About the authors

Vladimir I. Starodubov

Russian Research Institute of Health

Email: starodubov@mednet.ru
ORCID iD: 0000-0002-3625-4278
SPIN-code: 7223-9834

MD, PhD, Professor, Academician of the RAS

Russian Federation, Moscow

Valery V. Beregovykh

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: beregovykh@ramn.ru
ORCID iD: 0000-0002-0210-4570
SPIN-code: 5940-7554

PhD in Technical Sciences, Professor, Academician of the RAS

Russian Federation, Moscow

Vasily G. Akimkin

Central Research Institute of Epidemiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing

Email: vgakimkin@yandex.ru
ORCID iD: 0000-0003-4228-9044
SPIN-code: 4038-7455

MD, PhD, Professor, Academician of the RAS

Russian Federation, 3a, Novogireevskaya str., 111123, Moscow

Tatiana A. Semenenko

National Research Center of Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya

Email: meddy@inbox.ru
ORCID iD: 0000-0002-6686-9011
SPIN-code: 8375-2270

MD, PhD, Professor

Russian Federation, Moscow

Svetlana V. Ugleva

Central Research Institute of Epidemiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing

Author for correspondence.
Email: uglevas@bk.ru
ORCID iD: 0000-0002-1322-0155
SPIN-code: 8840-5814

MD, PhD, Associate Professor

Russian Federation, 3a, Novogireevskaya str., 111123, Moscow

Sergey N. Avdeev

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: serg_avdeev@list.ru
ORCID iD: 0000-0002-5999-2150
SPIN-code: 1645-5524

MD, PhD, Professor, Corresponding Member of the RAS

Russian Federation, Moscow

Kirill A. Zykov

Pulmonology Scientific Research Institute under Federal Medical and Biological Agency of Russian Federation; А.I. Yevdokimov Moscow State University of Medicine and Dentistry

Email: kiriliaz@inbox.ru
ORCID iD: 0000-0003-3385-2632
SPIN-code: 6269-7990

MD, PhD, Professor of the RAS

Russian Federation, Moscow; Moscow

Tatiana N. Trofimova

Pavlov First St. Petersburg State Medical University

Email: ttrofimova@sogaz-clinic.ru
ORCID iD: 0000-0003-4871-2341
SPIN-code: 9733-2755

MD, PhD, Professor

Russian Federation, St. Petersburg

Nana V. Pogosova

National Medical Research Center of Cardiology named after Academician E.I. Chazov

Email: nanapogosova@gmail.com
ORCID iD: 0000-0002-4165-804X
SPIN-code: 4168-6400

MD, PhD, Professor

Russian Federation, Moscow

Sergey N. Perekhodov

А.I. Yevdokimov Moscow State University of Medicine and Dentistry; Professor G.A. Zakharyin Tuberculosis Clinical Hospital No. 3

Email: persenmd@mail.ru
ORCID iD: 0000-0001-7166-0290
SPIN-code: 8770-6877

MD, PhD, Professor

Russian Federation, Moscow; Moscow

Stanislav N. Kuzin

Central Research Institute of Epidemiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing

Email: kuzin@cmd.su
ORCID iD: 0000-0002-0616-9777
SPIN-code: 1372-7623

MD, PhD, Professor

Russian Federation, 3a, Novogireevskaya str., 111123, Moscow

Svetlana B. Yacyshina

Central Research Institute of Epidemiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing

Email: svetlana.yatsyshina@pcr.ms
ORCID iD: 0000-0003-4737-941X
SPIN-code: 7156-2948

PhD in Biology, Senior Research Associate

Russian Federation, 3a, Novogireevskaya str., 111123, Moscow

Vadim V. Petrov

Central Research Institute of Epidemiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing

Email: petrov@pcr.ms
ORCID iD: 0000-0002-3503-2366
SPIN-code: 9852-8292

head of the scientific group for the development of new molecular biological technologies

Russian Federation, 3a, Novogireevskaya str., 111123, Moscow

Kamil F. Khafizov

Central Research Institute of Epidemiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing

Email: khafizov@cmd.su
ORCID iD: 0000-0001-5524-0296
SPIN-code: 9082-5749

PhD in Biology

Russian Federation, 3a, Novogireevskaya str., 111123, Moscow

Dmitry V. Dubodelov

Central Research Institute of Epidemiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing

Email: dubodelov@cmd.su
ORCID iD: 0000-0003-3093-5731
SPIN-code: 4860-7909

MD, PhD

Russian Federation, 3a, Novogireevskaya str., 111123, Moscow

Gasan A. Gasanov

Central Research Institute of Epidemiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing

Email: gasanovgt500@gmail.com
ORCID iD: 0000-0002-0121-521X
SPIN-code: 9726-9380
Russian Federation, 3a, Novogireevskaya str., 111123, Moscow

Nino Kh. Svanadze

Central Research Institute of Epidemiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing

Email: svanadze@cmd.su
ORCID iD: 0000-0001-7524-3080

MD

Russian Federation, 3a, Novogireevskaya str., 111123, Moscow

Anna S. Cherkashina

Central Research Institute of Epidemiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing

Email: cherkashina@pcr.ms
ORCID iD: 0000-0001-7970-7495
SPIN-code: 7854-7358

PhD in Chemistry

Russian Federation, 3a, Novogireevskaya str., 111123, Moscow

Evgeny A. Sinitsyn

Pulmonology Scientific Research Institute under Federal Medical and Biological Agency of Russian Federation; А.I. Yevdokimov Moscow State University of Medicine and Dentistry

Email: sinymlad@list.ru
ORCID iD: 0000-0002-8813-5932
SPIN-code: 3156-7024

Chief Physician of the Medical Center

Russian Federation, Moscow; Moscow

Anna V. Rvacheva

А.I. Yevdokimov Moscow State University of Medicine and Dentistry

Email: arvatcheva@mail.ru
ORCID iD: 0000-0001-9277-2291
SPIN-code: 5267-9598

MD, PhD

Russian Federation, Moscow

Natal'ya V. Sergeeva

Professor G.A. Zakharyin Tuberculosis Clinical Hospital No. 3

Email: Tkb_3@mail.ru

assistant of the Department of Infectious Diseases

Russian Federation, Moscow

Tatiana A. Polosova

А.I. Yevdokimov Moscow State University of Medicine and Dentistry

Email: uglevas@bk.ru

MD, PhD, Associate Professor

Russian Federation, Moscow

Alexandra A. Zykova

А.I. Yevdokimov Moscow State University of Medicine and Dentistry

Email: zykova.aal@medsigroup.ru
ORCID iD: 0000-0001-9577-4815

MD, PhD

Russian Federation, Moscow

Dmitrii A. Zelenin

А.I. Yevdokimov Moscow State University of Medicine and Dentistry; City Clinical Hospital named after V.P. Demihov

Email: zelenin@68gkb.ru
ORCID iD: 0000-0001-6622-4734
SPIN-code: 9418-3070

MD, PhD

Russian Federation, Moscow; Moscow

Mihail Yu. Gorbenko

City Clinical Hospital named after V.P. Demihov

Email: gorbenko@pochta.ru
ORCID iD: 0000-0003-4678-5459
SPIN-code: 8064-1419

MD, PhD

Russian Federation, Moscow

Irina S. Rodyukova

City Clinical Hospital named after V.P. Demihov; Pirogov Russian National Research Medical University (Pirogov Medical University)

Email: irina.rodyukova@gmail.com
ORCID iD: 0000-0001-9548-6426
SPIN-code: 8161-4082

MD, PhD, Associate Professor

Russian Federation, Moscow; Moscow

Nikolay I. Chaus

City Clinical Hospital named after V.P. Demihov; Russian Medical Academy of Continuous Professional Education

Email: nikchaus@yandex.ru
ORCID iD: 0000-0001-5891-3417

MD, PhD, Associate Professor

Russian Federation, Moscow; Moscow

Artem V. Snitsar

City Clinical Hospital named after V.P. Demihov

Email: snitsar@68gkb.ru
ORCID iD: 0000-0001-6053-4651
SPIN-code: 3059-5317

MD

Russian Federation, Moscow

References

  1. Wuhan Municipal Health Commission. Report of clustering pneumonia of unknown etiology in Wuhan City. Wuhan, China: Wuhan Municipal Health Commission. Available from: http://wjw.wuhan.gov.cn/ front/web/showDetail/2019123108989 (In Chin.)
  2. COVID-19 Research and Innovation. Powering the world’s pandemic response – now and in the future. Available from: https://cdn.who.int/media/docs/default-source/blue-print/achievement-report-_grif_web_finalversion15.pdf?sfvrsn=39052c73_9&download=true
  3. COVID-19, MERS & SARS/NIH: National Institute of Allergy and Infectious Diseases. (n.d.). Retrieved September 6, 2020. Available from: https://www.niaid.nih.gov/diseases-conditions/covid-19
  4. Коронавирус. Available from: https://coronavirus-monitor.info/
  5. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA. 2020;323(20):2052–2059. doi: https://doi.org/10.1001/jama.2020.6775
  6. Xu J, Xiao W, Liang X, et al. A meta-analysis on the risk factors adjusted association between cardiovascular disease and COVID-19 severity. BMC Public Health. 2021;21(1):1533. doi: https://doi.org/10.1186/s12889-021-11051-w
  7. Tian W, Jiang W, Yao J. Predictors of mortality in hospitalized COVID-19 patients: A systematic review and meta-analysis. J Med Virol. 2020;92(10):1875–1883. doi: https://doi.org/10.1002/jmv.26050
  8. Бойцов С.А., Погосова Н.В., Палеев Ф.Н., и др. Клиническая картина и факторы, ассоциированные с неблагоприятными исходами у госпитализированных пациентов с новой коронавирусной инфекцией COVID-19 // Кардиология. — 2021. — Т. 61. — № 2. — С. 4–14. [Boytsov SA, Pogosova NV, Paleev FN, et al. Clinical Characteristics and Factors Associated with Poor Outcomes in Hospitalized Patients with Novel Coronavirus Infection COVID-19. Kardiologiia. 2021;61(2):4–14. (In Russ.)] doi: https://doi.org/10.18087/cardio.2021.2.n1532
  9. Шляхто Е.В., Конради А.О., Арутюнов Г.П., и др. Руководство по диагностике и лечению болезней системы кровообращения в контексте пандемии COVID-19 // Российский кардиологический журнал. — 2020. — Т. 25. — № 3. — С. 3801. [Shlyakho EV, Konradi AO, Arutyunov GP, et al. Guidelines for the diagnosis and treatment of circulatory diseases in the context of the COVID-19 pandemic. Russian Journal of Cardiology. 2020;25(3):3801. (In Russ.)] doi: https://doi.org/10.15829/1560-4071-2020-3-3801
  10. Banerjee A, Chen S, Pasea L, et al. Excess deaths in people with cardiovascular diseases during the COVID-19 pandemic. Eur J Prev Cardiol. 2021;28(14):1599–1609. doi: https://doi.org/10.1093/eurjpc/zwaa155
  11. Ayoubkhani D, Khunti K, Nafilyan V, et al. Post-covid syndrome in individuals admitted to hospital with COVID-19: retrospective cohort study. BMJ. 2021;372:n693. doi: https://doi.org/10.1136/bmj.n693
  12. Xie Y, Xu E, Bowe B, et al. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022;28(3):583–590. doi: https://doi.org/10.1038/s41591-022-01689-3
  13. Smeeth L, Thomas SL, Hall AJ, et al. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 2004;351(25):2611–2618. doi: https://doi.org/10.1056/NEJMoa041747
  14. Libby P, Luscher T. COVID-19 is, in the end, an endothelial disease. Eur Heart J. 2020;41(32):3038–3044. doi: https://doi.org/10.1093/eurheartj/ehaa623
  15. Бурячковская Л.И., Мелькумянц А.М., Ломакин Н.В., и др. Повреждение сосудистого эндотелия и эритроцитов у больных COVID-19 // Consilium Medicum. — 2021. — Т. 23. — № 6. — С. 469–476. [Buryachkovskaya LI, Melkumyants AM, Lomakin NV, et al. Injury of vascular endothelium and erythrocytes in COVID-19 patients. Consilium Medicum. 2021;23(6):469–476. (In Russ.)] doi: https://doi.org/10.26442/20751753.2021.6.200939
  16. Ahmed H, Patel K, Greenwood DC, et al. Long-term clinical outcomes in survivors of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome coronavirus (MERS) outbreaks after hospitalization or ICU admission: a systematic review and meta-analysis. J Rehabil Med. 2020;52(5):jrm00063. doi: https://doi.org/10.2340/16501977-2694
  17. Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594(7862):259–264. doi: https://doi.org/10.1038/s41586-021-03553-9
  18. Арутюнов Г.П., Тарловская Е.И., Арутюнов А.Г., и др. Международный регистр «Анализ динамики коморбидных заболеваний у пациентов, перенесших инфицирование SARS-CoV-2 (aктив SARS-CoV-2)»: анализ 1000 пациентов // Российский кардиологический журнал. — 2020. — Т. 25. — № 11. — С. 4165. [Arutyunov GP, Tarlovskaya EI, Arutyunov AG. International register “Dynamics analysis of comorbidities in SARS-CoV-2 survivors” (AKTIV SARS-CoV-2): analysis of 1,000 patients. Russian Journal of Cardiology. 2020;25(11):4165. (In Russ.)] doi: https://doi.org/10.15829/1560-4071-2020-4165
  19. Погосова Н.В., Палеев Ф.Н., Аушева А.К., и др. Последствия COVID-19 на отдаленном этапе после госпитализации // Рациональная фармакотерапия в кардиологии. — 2022. — Т. 18. — № 2. — С. 118–126. [Pogosova NV, Paleev FN, Ausheva AK, et al. Sequelae of COVID-19 at long-term follow-up after hospitalization. Rational Pharmacotherapy in Cardiology. 2022;18(2):118–126. (In Russ.)] doi: https://doi.org/10.20996/1819-6446-2022-04-03
  20. Ti LK, Ang LS, Foong TW, et al. What we do when a COVID-19 patient needs an operation: operating room preparation and guidance. Can J Anaesth. 2020;67(6):756–758. doi: https://doi.org/10.1007/s12630-020-01617-4
  21. Gu J, Han B, Wang J. COVID-19: Gastrointestinal Manifestations and Potential Fecal-Oral Transmission. Gastroenterology. 2020;158(6):1518–1519. doi: https://doi.org/10.1053/j.gastro.2020.02.054
  22. Bai Y, Yao L, Wei T, et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA. 2020;323(14):1406–1407. doi: https://doi.org/10.1001/jama.2020.2565
  23. Kampf G, Todt D, Pfaender S, et al. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect. 2020;104(3):246–251. doi: https://doi.org/10.1016/j.jhin.2020.01.022
  24. Письмо Роспотребнадзора от 11.04.2020 № 02/6673-2020-32 «О направлении рекомендаций по применению СИЗ для различных категорий граждан при рисках инфицирования COVID-19» (вместе с МР 3.1/3.5.0172/1-20. 3.1. Профилактика инфекционных болезней. 3.5. Дезинфектология. Рекомендации по применению средств индивидуальной защиты (в том числе многоразового использования) для различных категорий граждан при рисках инфицирования COVID-19. Методические рекомендации).
  25. Sartelli M, Chichom-Mefire A, Labricciosa FM, et al. The management of intra-abdominal infections from a global perspective: 2017 WSES guidelines for management of intra-abdominal infections. World J Emerg Surg. 2017;12:29. doi: https://doi.org/10.1186/s13017-017-0141-6
  26. Di Saverio S, Podda M, De Simone B, et al. Diagnosis and treatment of acute appendicitis: 2020 update of the WSES Jerusalem guidelines. World J Emerg Surg. 2020;15(1):27. doi: https://doi.org/10.1186/s13017-020-00306-3
  27. De Simone B, Chouillard E, Di Saverio S, et al. Emergency surgery during the COVID-19 pandemic: what you need to know for practice. Ann R Coll Surg Engl. 2020;102(5):323–332. doi: https://doi.org/10.1308/rcsann.2020.0097
  28. Ansaloni L, Pisano M, Coccolini F, et al. 2016 WSES guidelines on acute calculous cholecystitis. World J Emerg Surg. 2016;11:25. doi: https://doi.org/10.1186/s13017-016-0082-5
  29. Loozen CS, van Santvoort HC, van Duijvendijk P, et al. Laparoscopic cholecystectomy versus percutaneous catheter drainage for acute cholecystitis in high risk patients (CHOCOLATE): multicentre randomised clinical trial. BMJ. 2018;363:k3965. doi: https://doi.org/10.1136/bmj.k3965
  30. Щеголев А.А. (ред.). Желчекаменная болезнь: учебно-метод. пособие. — М.: РНИМУ, 2015. — 35 с. [Shchegolev AA (red.). Zhelchekamennaya bolezn': uchebno-metod. posobie. Moscow: RNIMU; 2015. 35 s. (In Russ.)]
  31. Pisano M, Zorcolo L, Merli C, et al. 2017 WSES guidelines on colon and rectal cancer emergencies: obstruction and perforation. World J Emerg Surg. 2018;13:36. doi: https://doi.org/10.1186/s13017-018-0192-3
  32. Ten Broek RP, Krielen P, Di Saverio S, et al. Bologna guidelines for diagnosis and management of adhesive small bowel obstruction (ASBO): 2017 update of the evidence-based guidelines from the World Society of Emergency Surgery ASBO working group. World J Emerg Surg. 2018;13:24. doi: https://doi.org/10.1186/s13017-018-0185-2
  33. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033–2040. doi: https://doi.org/10.1182/blood.2020006000
  34. Bahloul M, Chaari A, Ben Algia N, et al. Pulmonary embolism in intensive care unit “literature review”. Trends Anaesth Crit. 2012;2(1):25–29. doi: https://doi.org/10.1016/j.tacc.2011.11.005
  35. Reyes Valdivia A, Aracil Sanus E, Duque Santos Á, et al. Adapting vascular surgery practice to the current COVID-19 era at a tertiary academic center in Madrid. Ann Vasc Surg. 2020;67:1–5. doi: https://doi.org/10.1016/j.avsg.2020.06.001
  36. Ivashchenko AA, Dmitriev KA, Vostokova NV, et al. AVIFAVIR for Treatment of Patients with Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial. Clin Infect Dis. 2021;73(3):531–534. doi: https://doi.org/10.1093/cid/ciaa1176
  37. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 — Final Report. N Engl J Med. 2020;383:1813–1826. doi: https://doi.org/10.1056/NEJMoa2007764
  38. Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for Oral Treatment of COVID-19 in Nonhospitalized Patients. N Engl J Med. 2022;386(6):509–520. doi: https://doi.org/10.1056/NEJMoa2116044
  39. Hammond J, Leister-Tebbe H, Gardner A, et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with COVID-19. N Engl J Med. 2022;386(15):1397–1408. doi: https://doi.org/10.1056/NEJMoa2118542
  40. Bruzzesi E, Ranzenigo M, Castagna A, et al. Neutralizing monoclonal antibodies for the treatment and prophylaxis of SARS-CoV-2 infection. New Microbiol. 2021;44(3):135–144.
  41. RECOVERY Collaborative Group; Horby P, Lim WS, Emberson JR, et al. Dexamethasone in Hospitalized Patients with COVID-19. N Engl J Med. 2021;384(8):693–704. doi: https://doi.org/10.1056/NEJMoa2021436
  42. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group; Sterne JAC, Murthy S, Diaz JV, et al. Association Between Administration of Systemic Corticosteroids And Mortality Among Critically Ill Patients with COVID-19: A Meta-Analysis. JAMA. 2020;324(13):1330–1341. doi: https://doi.org/10.1001/jama.2020.17023
  43. REMAP-CAP Investigators; Gordon AC, Mouncey PR, Al-Beidh F, et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with COVID-19. N Engl J Med. 2021;384(16):1491–1502. doi: https://doi.org/10.1056/NEJMoa2100433
  44. RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10285):1637–1645. doi: https://doi.org/10.1016/S0140-6736(21)00676-0
  45. ATTACC Investigators; ACTIV-4a Investigators; REMAP-CAP Investigators; Lawler PR, Goligher EC, Berger JS, et al. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with COVID-19. N Engl J Med. 2021;385(9):790–802. doi: https://doi.org/10.1056/NEJMoa2105911
  46. Баутин А.Е., Авдеев С.Н., Сейлиев А.А., и др. Ингаляционная терапия сурфактантом в комплексном лечении тяжелой формы COVID-19-пневмонии // Туберкулез и болезни легких. — 2020. — Т. 98. — № 9. — С. 6–12. [Bautin АE, Аvdeev SN, Seyliev АА, et al. А. Inhalation surfactant therapy in the integrated treatment of severe COVID-19 pneumonia. Tuberculosis and Lung Diseases. 2020;98(9):6–12. (In Russ.)] doi: http://doi.org/10.21292/2075-1230-2020-98-9-6-12
  47. Avdeev SN, Trushenko NV, Chikina SY, et al. Beneficial effects of inhaled surfactant in patients with COVID-19-associated acute respiratory distress syndrome. Respir Med. 2021;185:106489. doi: https://doi.org/10.1016/j.rmed.2021.106489
  48. Tsareva NA, Avdeev SN, Kosanovic D, et al. Inhaled iloprost improves gas exchange in patients with COVID-19 and acute respiratory distress syndrome. Crit Care. 2021;25(1):258. doi: https://doi.org/10.1186/s13054-021-03690-7
  49. Авдеев С.Н., Царева Н.А., Мержоева З.М., и др. Практические рекомендации по кислородотерапии и респираторной поддержке пациентов с COVID-19 на дореанимационном этапе // Пульмонология. — 2020. — Т. 30. — № 2. — С. 151–163. [Avdeev SN, Tsareva NA, Merzhoeva ZM, et al. Practical guidelines for oxygen therapy and respiratory support for patients with COVID-19 in the pre-life support. Pulmonology. 2020;30(2):151–163 (In Russ.)] doi: https://doi.org/10.18093/0869-0189-2020-30-2-151-163
  50. Faculty of Intensive Care Medicine, Intensive Care Society, Association of Anaesthetists and Royal College of Anaesthetists. Critical care preparation and management in the COVID-19 pandemic. Available at: https://www.icmanaesthesiacovid-19.org/critical-care-preparation-and-management-in-the-covid-19-pandemic
  51. Oranger M, Gonzalez-Bermejo J, Dacosta-Noble P, et al. Continuous positive airway pressure to avoid intubation in SARS-CoV-2 pneumonia: a two-period retrospective case-control study. Eur Respir J. 2020;56(2):2001692. doi: https://doi.org/10.1183/13993003.01692-2020
  52. Bellani G, Grasselli G, Cecconi M, et al. Noninvasive Ventilatory Support of COVID-19 Patients Outside the Intensive Care Units. Ann Am Thorac Soc. 2021;18(6):1020–1026. doi: https://doi.org/10.1513/AnnalsATS.202008-1080OC
  53. Avdeev S, Yaroshetskiy A, Tsareva N, et al. Noninvasive ventilation for acute hypoxemic respiratory failure in patients with COVID-19. Am J Emerg Med. 2021;39:154–157. doi: https://doi.org/10.1016/j.ajem.2020.09.075
  54. Grieco DL, Menga LS, Cesarano M, et al. Effect of helmet noninvasive ventilation vs high-flow nasal oxygen on days free of respiratory support in patients with COVID-19 and moderate to severe hypoxemic respiratory failure: the HENIVOT randomized clinical trial. JAMA. 2021;325(17):1731–1743. doi: https://doi.org/10.1001/jama.2021.4682
  55. Perkins GD, Ji C, Connolly BA, et al. Effect of Noninvasive Respiratory Strategies on Intubation or Mortality Among Patients with Acute Hypoxemic Respiratory Failure and COVID-19: The RECOVERY-RS Randomized Clinical Trial. JAMA. 2022;327(6):546–558. doi: https://doi.org/10.1001/jama.2022.0028
  56. Авдеев С.Н. Неинвазивная вентиляция легких при новой коронавирусной инфекции COVID-19 // Пульмонология. — 2020. — Т. 30. — № 5. — С. 679–687. [Avdeev SN. Non-invasive ventilation in patients with novel coronavirus infection COVID-19. Pulmonologiya. 2020;30(5):679-687.] (In Russ.) doi: https://doi.org/10.18093/0869-0189-2020-30-5-679-687
  57. Pelosi P, Tubiolo D, Mascheroni D, et al. Effects of the prone position on respiratory mechanics and gas exchange during acute lung injury. Am J Respir Crit Care Med. 1998;157(2):387–393. doi: https://doi.org/10.1164/ajrccm.157.2.97-04023
  58. Ehrmann S, Li J, Ibarra-Estrada M, et al. Awake Prone Positioning Meta-Trial Group. Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial. Lancet Respir Med. 2021;9(12):1387–1395. doi: https://doi.org/10.1016/S2213-2600(21)00356-8
  59. Avdeev SN, Nekludova GV, Trushenko NV, et al. Lung ultrasound can predict response to the prone position in awake non-intubated patients with COVID-19 associated acute respiratory distress syndrome. Crit Care. 2021;25(1):35. doi: https://doi.org/10.1186/s13054-021-03472-1
  60. WHO Coronavirus (COVID-19) Dashboard. Available from: https://covid19.who.int (accessed: 11.05.2022).
  61. Отчет о текущей ситуации по борьбе с коронавирусом. Коммуникационный центр Правительства Российской Федерации. 11.05.2022. [Otchet o tekushei situacii po bor’be s koronavirusom. Available from: Kommunikacionnii centr Pravitel’stva Rossiiskoi Federacii. 11.05.2022. (In Russ.)] Available from: https://стопкоронавирус.рф
  62. Оковитый С.В. Клиническая фармакология иммунодепрессантов // Обзоры по клинической фармакологии и лекарственной терапии. — 2003. — Т. 2. — № 2. — С. 2–34. [Okovityj SV. Klinicheskaya farmakologiya immunodepressantov. Obzory po klinicheskoj farmakologii i lekarstvennoj terapii. 2003;2(2):2–34. (In Russ.)]
  63. COVID-19 Excess Mortality Collaborators. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21. Lancet. 2022;399(10334):1513–1536. doi: https://doi.org/10.1016/S0140-6736(21)02796-3
  64. Shi Y, Wang Y, Shao C, et al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ. 2020;27(5):1451–1454. doi: https://doi.org/10.1038/s41418-020-0530-3
  65. Козлов В.А., Савченко А.А., Кудрявцев И.В., и др. Клиническая иммунология. — Красноярск: Поликор, 2020. — 386 с. [Kozlov VA, Savchenko AA, Kudryavcev IV, i dr. Klinicheskaya immunologiya. Krasnoyarsk: Polikor; 2020. 386 s. (In Russ.)]
  66. Wang J, Yang W, Chen P, et al. The proportion and effect of corticosteroid therapy in patients with COVID-19 infection: A systematic review and meta-analysis. PLoS One. 2021;16(4):e0249481. doi: https://doi.org/10.1371/journal.pone.0249481
  67. Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 15. 22.02.2022. Available from: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/059/392/original/ВМР_COVID-19_V15.pdf
  68. Snow TAC, Saleem N, Ambler G, et al. Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials. Intensive Care Med. 2021;47(6):641–652. doi: https://doi.org/10.1007/s00134-021-06416-z
  69. Selvaraj V, Khan MS, Bavishi C, et al. Tocilizumab in Hospitalized Patients with COVID-19: A Meta Analysis of Randomized Controlled Trials. Lung. 2021;199(3):239–248. doi: https://doi.org/10.1007/s00408-021-00451-9
  70. RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10285):1637–1645. doi: https://doi.org/10.1016/S0140-6736(21)00676-0
  71. Patoulias D, Doumas M, et al. Janus kinase inhibitors and major COVID-19 outcomes: time to forget the two faces of Janus! A meta-analysis of randomized controlled trials. Clin Rheumatol. 2021;40(11):4671–4674. doi: https://doi.org/10.1007/s10067-021-05884-4
  72. Ma S, Xu C, Liu Sh, et al. Efficacy and safety of systematic corticosteroids among severe COVID‐19 patients: a systematic review and meta‐analysis of randomized controlled trials. Signal Transduct Target Ther. 2021;6(1):83. doi: https://doi.org/10.1038/s41392-021-00521-7
  73. RECOVERY Collaborative Group; Horby P, Lim WS, Emberson JR, et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384(8):693–704. doi: https://doi.org/10.1056/NEJMoa2021436
  74. The COVID STEROID 2 Trial Group; Munch MW, Myatra SN, Vijayaraghavan BKT, et al. Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia: The COVID STEROID 2 Randomized Trial. JAMA. 2021;326(18):1807–1817. doi: https://doi.org/10.1001/jama.2021.18295
  75. Jamaati H, Hashemian SMR, Farzanegan B, et al. No clinical benefit of high dose corticosteroid administration in patients with COVID-19: A preliminary report of a randomized clinical trial. Eur J Pharmacol. (2021);897:173947. doi: https://doi.org/10.1016/j.ejphar.2021.173947
  76. Oganesyan A., Zykov K, Surovoy Y, et al. Target Groups for a Short Dexamethasone Course among Critically Ill COVID-19 Patients. Crit Care Res Pract. 2021;2021:5557302. doi: https://doi.org/10.1155/2021/5557302
  77. Jung C, Wernly B, Fjølner J, et al. and the COVIP study group. Steroid use in elderly critically ill COVID-19 patients. Eur Respir J. 2021;58(4):2100979. doi: https://doi.org/10.1183/13993003.00979-2021
  78. Duarte MBO, Leal F, et al. Outcomes of COVID-19 Patients under Cytotoxic Cancer Chemotherapy in Brazil. Cancers (Basel). 2020;12(12):3490. doi: https://doi.org/10.3390/cancers12123490
  79. Синицын Е.А., Зыкова А.А., Шамин Р.В., и др. Эффективность и безопасность применения ингаляций ультранизких доз мелфалана в лечении госпитализированных пациентов с COVID-19 // Acta Biomedica Scientifica. — 2022. — Т. 7. — № 2. — С. 12–23. [Sinitsyn EA, Zykova AA, Shamin RV, et al. Efficacy and safety of ultra-low dose inhaled melphalan in the treatment of hospitalized patients with COVID-19. Acta Biomedica Scientifica. 2022;7(2):12–23. (In Russ.)] doi: https://doi.org/10.29413/ABS.2022-7.2.2

Supplementary files

Supplementary Files
Action
1. Fig. 1

Download (329KB)
Indexing metadata
2. Fig. 2

Download (377KB)
Indexing metadata
3. Fig. 3

Download (147KB)
Indexing metadata
4. Fig. 4

Download (185KB)
Indexing metadata

Copyright (c) 2022 "Paediatrician" Publishers LLC



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies